Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
about
Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancerTreatment including anthracyclines versus treatment not including anthracyclines for childhood cancerTreatment including anthracyclines versus treatment not including anthracyclines for childhood cancerA Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue SarcomasChildren's Oncology Group's 2013 blueprint for research: Soft tissue sarcomasThe surgical management of paediatric bladder and prostate rhabdomyosarcomaEmbryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targetingMolecular biology and therapeutics in musculoskeletal oncology.Aberrant CDK4 amplification in refractory rhabdomyosarcoma as identified by genomic profilingRhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studiesMyogenin, AP2β, NOS-1, and HMGA2 are surrogate markers of fusion status in rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children's oncology group.Rhabdomyosarcoma in adolescent and young adult patients: current perspectives.Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation.Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis.Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's OncPrognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group.Primary alveolar rhabdomyosarcoma of the bone: two cases and review of the literatureGene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group.Curcumin potentiates rhabdomyosarcoma radiosensitivity by suppressing NF-κB activityComparison of PET-CT and conventional imaging in staging pediatric rhabdomyosarcomaPediatric soft tissue sarcomas.Local therapy for rhabdomyosarcoma of the hands and feet: is amputation necessary? A report from the Children's Oncology Group.Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology GroupRegional nodal involvement and patterns of spread along in-transit pathways in children with rhabdomyosarcoma of the extremity: a report from the Children's Oncology Group.Tumor volume and patient weight as predictors of outcome in children with intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.Modeling of the human alveolar rhabdomyosarcoma Pax3-Foxo1 chromosome translocation in mouse myoblasts using CRISPR-Cas9 nuclease.Rhabdomyosarcoma in infants younger than 1 year: a report from the Children's Oncology Group.Safety and diagnostic accuracy of tumor biopsies in children with cancer.Cost minimization analysis of two treatment regimens for low-risk rhabdomyosarcoma in children: a report from the Children's Oncology GroupRhabdomyosarcoma of the head and neck in childrenUrogenital tumours in childhood.Inhibiting phosphorylation of the oncogenic PAX3-FOXO1 reduces alveolar rhabdomyosarcoma phenotypes identifying novel therapy optionsLocal control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 studyActivating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma.The inconvenience of convenience cohorts: rhabdomyosarcoma and the PAX-FOXO1 biomarker.Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology GroupDense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology GroupAlveolar rhabdomyosarcoma confined to the bone marrow with no identifiable primary tumour using FDG-PET/CT.Higher rates of metastatic disease may explain the declining trend in Swedish paediatric rhabdomyosarcoma survival rates.
P2860
Q24193790-12B04B52-E971-43D1-A446-E6F72E131AFDQ24234833-B978C4E6-F945-4845-AD25-B9BF89428A1EQ24241602-C5A5012A-0F32-4FE0-88C9-01DC5D723323Q26782842-F5C19AA8-32FF-464A-A68E-25E58F2237EFQ26825000-07A80D5E-F3FB-4C6D-B83E-C36C4986D25CQ27015190-C45DF750-35F9-4E6E-BF38-06BB3DA0A70AQ30426842-418DA059-964E-4846-94E5-6F2B930E6146Q30426953-8BE1CB97-0271-464B-A40B-C6F31B68FBB8Q30563970-B640771C-A1E9-4C71-A04A-9668F9BD6A85Q33559468-0CF0EA69-F902-4ED5-8BE2-6774C4024FCDQ33567593-E4984C96-7864-4F9B-BA13-39DEE638DFC4Q33800135-8D653A71-CA99-4D8A-BC0E-B1A030A98C3BQ33901521-C197DA6D-8C4F-41F8-9BED-1D2003BE7255Q33995820-73608566-86A1-4414-B9D2-BFFF957EB4BBQ34069279-AEE03046-6E1F-462E-8BE2-EF43D5DCEC3EQ34402527-05D5F216-0CB9-4CE9-A30F-9C0507E5CD10Q34490071-605ECD97-0BDA-4273-932D-8304F16122D6Q34542936-DE6F986F-B8C4-4B30-82AC-7E778876B4A4Q34578460-8F19F475-FA18-4DAB-A07A-0F977A8A8677Q34585809-B0AAA3B7-31B5-4636-A981-2F85461410A4Q34706841-EFFB0688-91C2-4771-9342-A639A95ECBB0Q34754962-E2A014E2-6A17-4F41-94BA-4244DE693645Q34786004-2357B4F0-39CE-4F47-B6D1-B25D3B232C3AQ34879284-9A074829-F336-48F9-A42B-0E91929831ECQ35048131-21E175AB-2ACA-4944-B7D4-9AADE0FE481CQ35051029-9D9241C1-26A9-463B-875C-3F158DF26297Q35058021-DA4E5110-E011-4638-9E67-125B44886326Q35119012-614E5A8A-714D-4D2E-852C-90C53B83CEFCQ35202350-0ED49996-2893-4BF2-A13C-71472E091B57Q35207522-6447BD9B-6AA5-4E53-90B5-7B83C83E4FE4Q35648994-868EF013-1227-47F7-89D8-1500C402762AQ35697570-E99EC6D5-6788-4FA7-BEA9-3DA037F810EDQ35818209-1BBE2BAB-4499-45ED-9CC9-BA2BC612BF1FQ35834688-4117DDC4-EAEB-4BD1-BFFF-F0D63A8A05EEQ35936863-697BB0D1-F444-445C-9477-DBD352B86C6BQ36084235-24083DDB-B2D6-48EF-B7CC-325AA1294714Q36175120-48D25A6C-16E2-4F0D-BB64-CB5CACC32C8EQ36219115-06C2F788-9767-40DD-B764-13804A65D2B9Q36298578-D6BA51B7-47FC-4A5F-B1C2-1E19FCC13187Q36536619-D9EE7DBD-A247-4BB2-87CA-541BA3B43AFA
P2860
Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Analysis of prognostic factors ...... the Children's Oncology Group.
@ast
Analysis of prognostic factors ...... the Children's Oncology Group.
@en
Analysis of prognostic factors ...... the Children's Oncology Group.
@nl
type
label
Analysis of prognostic factors ...... the Children's Oncology Group.
@ast
Analysis of prognostic factors ...... the Children's Oncology Group.
@en
Analysis of prognostic factors ...... the Children's Oncology Group.
@nl
prefLabel
Analysis of prognostic factors ...... the Children's Oncology Group.
@ast
Analysis of prognostic factors ...... the Children's Oncology Group.
@en
Analysis of prognostic factors ...... the Children's Oncology Group.
@nl
P2093
P356
P1476
Analysis of prognostic factors ...... the Children's Oncology Group.
@en
P2093
Alberto S Pappo
Children's Oncology Group
James Anderson
Jane L Meza
William H Meyer
P304
P356
10.1200/JCO.2005.05.3801
P407
P577
2006-08-01T00:00:00Z